“Old” Antibiotics May Get Exclusivity Under New Law; 10 Drugs Could Benefit
Executive Summary
Drug manufacturers could get marketing exclusivity for a handful of old antibiotics under legislation passed by the House and Senate last month
You may also be interested in...
ViroPharma’s Failed Exclusivity Bid For Vancocin Could Spur Congress To Act
FDA’s decision that vancomycin oral capsules do not qualify for Hatch-Waxman marketing protection under a 2008 law could become the focus of a legislative “fix” in pending user fee bills if lawmakers disagree with the agency’s conclusion that only approval of a “significant new use” for older antibiotics warrants exclusivity.
Vancocin Generics Launch As FDA Finds ViroPharma’s Label Fails “Significant New Use” Test
FDA delivers an 87-page chef d'oeuvre that concludes the ViroPharma’s long-running battle to block ANDA approvals. In the citizen petition response, FDA rejects the firm’s scientific and legal arguments and concludes the antibiotic is not eligible for three years of Hatch-Waxman marketing exclusivity under a 2008 law. Although ViroPharma says it plans to sue FDA, the company may have bigger problems on its hands with an FTC investigation.
"Old" Antibiotics Face More Generic Pressure After FDA Denies 30-Month Stays
Teva's brief at-risk launch of the acne product Solodyn followed by a settlement with Medicis may serve as template.